Drug & intervention

caffeine

RxCUI 1886

Clinical trials20
Recruiting1
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Caffeine

Caffeine is a central nervous system (CNS) stimulant of the methylxanthine class and is the most commonly consumed psychoactive drug globally. It is mainly used for its eugeroic (wakefulness promoting), ergogenic (physical performance-enhancing), or nootropic (cognitive-enhancing) properties (particularly in workplace settings); it is also used recreationally, often in social settings. Caffeine acts by blocking the binding of adenosine at a number of adenosine receptor types, inhibiting the centrally depressant effects of adenosine and enhancing the release of acetylcholine. Caffeine has a three-dimensional structure similar to that of adenosine, which allows it to bind and block its receptors. Caffeine also increases cyclic AMP levels through nonselective inhibition of phosphodiesterase, increases calcium release from intracellular stores, and antagonizes GABA receptors, although these mechanisms typically occur at concentrations beyond usual human consumption. Caffeine is a bitter, white crystalline purine, a methylxanthine alkaloid, and is chemically related to the adenine and guanine bases of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). It is found in the seeds, fruits, nuts, or leaves of a number of plants native to Africa, East Asia, and South America and helps to protect them against herbivores and from competition by preventing the germination of nearby seeds, as well as encouraging consumption by select animals such as honey bees. The most common sources of caffeine for human consumption are the tea leaves of the Camellia sinensis plant and the coffee...

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

20 shown
Effect of CAFfeine on Cognition in Alzheimer's DiseaseNCT04570085 · 2021-03-01
RECRUITING
A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe SubstratesNCT06632990 · 2024-11-04
ACTIVE_NOT_RECRUITING
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or ObesityNCT06564441 · 2024-10-01
COMPLETED
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232 · 2022-07-08
COMPLETED
Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4NCT04246762 · 2021-11-16
COMPLETED
Metformin's Effect on Drug Metabolism in Patients With Type 2 DiabetesNCT04504045 · 2020-09-01
TERMINATED
A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinNCT03970798 · 2019-05-22
COMPLETED
Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and PravastatinNCT03131973 · 2017-05-13
COMPLETED
The Impact of Caffeine on Cognition in SchizophreniaNCT02832401 · 2016-09-02
COMPLETED
A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral SclerosisNCT02655614 · 2016-05-31
COMPLETED
A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 SubstratesNCT02211079 · 2014-09-01
COMPLETED
Caffeine as a Therapy for Parkinson's DiseaseNCT01738178 · 2014-04-01
COMPLETED
A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate CancerNCT02225093 · 2013-10-02
COMPLETED
Caffein Consumption and Response InhibitionNCT01815203 · 2013-03-01
COMPLETED
A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid ArthritisNCT01636557 · 2012-10-11
COMPLETED
Effect of Oral Caffeine and L-Citrulline Supplementation on Arterial Function in Healthy MalesNCT02214290 · 2012-09-01
COMPLETED
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid TumorsNCT01596647 · 2012-05-01
COMPLETED
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsNCT01402089 · 2012-01-01
COMPLETED
"Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous FatNCT00377975 · 2003-01-01
COMPLETED
Effect on Energy Metabolism at Cellular Level of Diet Plus Treatment With Ephedrine and Caffeine in ObesityNCT02048215 · 2000-02-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.